Intravitreal bevacizumab in choroidal neovascularization secondary to Grönblad-Strandberg syndrome: case report

Japiassú, Ricardo Miguel; Japiassú, Maria Augusta Castro Farias; Pecego, Mariana Gomes

doi:10.1590/s0004-27492008000300024

Cited by 5 publications

(2 citation statements)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45 All reports indicate an improvement of vision in the short term (Table 3). [46][47][48][49][50][51][52][53][54] The longest followup is approximately 2 years (range: 3-24 months). There are several interesting trends among studies of angioid-streak-related CNV treatment with antiangiogenic agents.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Section: Therapeutic Optionsmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

show abstract

“…The rarity of the disease prevented large series to be studied, and most case series did have a relatively short follow-up [28,[36][37][38][39][40][41][42][43]. However, the results were very encouraging.…”

Section: Treatment Of Cnvmentioning

confidence: 99%

Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients

Verbraak¹

2010

Anti-Vegf

View full text Add to dashboard Cite

The eye in patients with pseudoxanthoma elasticum, an autosomal recessive disease, shows several lesions, like peau d'orange, angioid streaks, comet lesions, and paired hyperpigmented smudges. The most devastating ocular complication is the development of choroidal neovascularizations (CNV). This exudative disease of the central retina leads to loss of visual acuity, and results of treatments in the past have been disappointing. From the present evidence it may be concluded that intravitreal antivascular endothelial growth factor (anti-VEGF) therapy with ranibizumab or bevacizumaab is beneficial for the treatment of CNV secondary to angioid streaks associated with PXE. Especially in the early stages of the disease, visual acuity can be maintained or even improved over a prolonged period of time, even with a low number of injections. Later in the course of the disease, when more widespread atrophic changes have occurred, the perspective is more bleak. Although there seem to be arguments to treat selected patients with a maintenance treatment of intravitreal injections once every 2 months, an as-needed regimen is the most used strategy. Patients need to be aware of the off-label nature of the treatment with anti-VEGF and also need to be informed about the possible increased risk of cardiovascular and/or thromboembolic events, although at present no definite proof has been documented of this higher risk in patients with or without PXE treated with intravitreal anti-VEGF. Overall, based on the evidence available, intravitreal treatment with anti-VEGF seems to be the best choice at present to treat patients with CNV secondary to angioid streaks and PXE.

show abstract

Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: A report of two patients

Özkaya

Alkın

Faiz

et al. 2014

Saudi Journal of Ophthalmology

View full text Add to dashboard Cite

The aim of this study is to report clinical course of choroidal neovascularization secondary to angioid streaks (AS) in two patients who underwent intravitreal bevacizumab therapy. Fundus examination, fluorescein angiography (FA) and optical coherence tomography (OCT) revealed the diagnosis of subfoveal classic choroidal neovascularization (CNV) in the right eye in patient 1 and in the left eye in patient 2. After three consecutive bevacizumab injections, visual acuity improved from 20/40 to 20/25 in patient 1 and from 20/80 to 20/50 in patient 2. After 3 months of therapy, additional bevacizumab injection was administered when the lesion showed recurrence. After a follow-up time of 24-months, patient 1 received 14 intravitreal bevacizumab injections; patient 2 received only 4 injections. Visual acuities remained stable at 20/32 and 20/50 in patient 1 and patient 2, respectively. Though, the patients of CNV secondary to AS showed similar clinical appearance at the beginning, this report provides the data for different responses to intravitreal bevacizumab therapy. While fewer injections were required to control the disease in one patient, the other patient needed much more injections for stabilization of the CNV. Further studies are required to understand the cause of varied treatment responses in those patients.

show abstract

Intravitreal bevacizumab in choroidal neovascularization secondary to Grönblad-Strandberg syndrome: case report

Cited by 5 publications

References 6 publications

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Antivascular Endothelial Growth Factor Treatment in Pseudoxanthoma Elasticum Patients

Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks: A report of two patients

Contact Info

Product

Resources

About